Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole?

BACKGROUND: BMI has been suggested to impact on estrogenic activity in patients receiving anastrozole resulting in a reduced treatment efficacy in obese women. Current evidence in this regard is controversially discussed. Since estradiol is inversely correlated with gonadotropins it can be assumed t...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:BMC Cancer
Asıl Yazarlar: Oberguggenberger, A., Meraner, V., Sztankay, M., Beer, B., Weigel, G., Oberacher, H., Kemmler, G., Czech, T., Holzner, B., Wildt, L., Sperner-Unterweger, B., Daniaux, M., Hubalek, M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2017
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5371265/
https://ncbi.nlm.nih.gov/pubmed/28351392
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3208-6
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller